54 / 116
Median OS in months (95% CI)
COMBO450
VEM
ENCO 300
33.6 (24.4–39.2)
16.9 (14.0–24.5)
23.5
HR (95% CI), 0.61 (0.47–0.79)
Nominal 2-sided
P
<0.0001
0
10
20
30
40
50
60
70
80
90
100
Overall Survival, %
Time (months)
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48
COMBO450
VEM
Censored patients
Reinhard Dummer
Abstract 9504. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus
binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
R Dummer
SG 1 año→ 76%
SG 2 años→ 58%
SG 3 años→ 47%